Last Price
36.88
Today's Change
+0.25 (0.68%)
Day's Change
36.36 - 37.79
Trading Volume
457,904
Market Cap
2 Billion
Shares Outstanding
64 Million
Avg Volume
488,661
Avg Price (50 Days)
40.84
Avg Price (200 Days)
41.72
PE Ratio
-15.76
EPS
-2.34
Earnings Announcement
20-Feb-2025
Previous Close
36.63
Open
36.99
Day's Range
36.36 - 37.79
Year Range
29.24 - 53.27
Trading Volume
457,904
1 Day Change
0.68%
5 Day Change
-1.81%
1 Month Change
-15.34%
3 Month Change
-12.11%
6 Month Change
-16.26%
Ytd Change
-9.81%
1 Year Change
-1.44%
3 Year Change
-15.66%
5 Year Change
10.88%
10 Year Change
10.88%
Max Change
10.88%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.